1.68

1.68 (-0.61%)

As of Feb 16, 2022

Kaleido Biosciences, Inc. [KLDO]

Source: 

Company Overview

We have initiated a process to explore a range of strategic alternatives to maximize shareholder value and have engaged professional advisors, including an investment banker to act as a strategic advisor for this process. Potential strategic alternatives that may be evaluated include a sale or merger of the Company or securing additional financing or partnerships that would enable further development of our programs. There can be no assurance that this strategic review process will result in our pursuing any transaction or that any transaction, if pursued, will be completed. We aim to run this strategic review process into mid-April 2022. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value. If the strategic process is unsuccessful, our Board may decide to pursue a dissolution and liquidation. In the event of such liquidation or other wind-down event, holders of our securities will likely suffer a total loss of their investment.

CountryUS
Headquartersbedfordmassachusetts
Phone Number(617) 674-9000
Industrybiological products (no diagnostic substances)
CEODaniel L. Menichella
Websitekaleido.com

Recent Stories